Cipher PharmaceuticalsTSX:CPH +0.80%100 FCF Margin % is 31.68% as of Mar. 2026, which is 42% below its 10-year median of 54.97. GuruFocus rates TSX:CPH with a GF Score™ of 100/100 and a GF Value™ of C$17.03 (Fairly Valued). The stock has 5 warning signs investors should review. Among 958 Drug Manufacturers companies, Cipher Pharmaceuticals ranks better than 99.06% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cipher Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cipher Pharmaceuticals FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cipher Pharmaceuticals's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Cipher Pharmaceuticals's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cipher Pharmaceuticals (TSX:CPH) has a FCF Margin % of 31.68% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Cipher Pharmaceuticals and its competitors. This is 42% below median its historical median of 54.97. Over the past decade, Cipher Pharmaceuticals' FCF Margin % has ranged from 20.47 to 75.50. According to the industry distribution chart, Cipher Pharmaceuticals ranks #9 out of 958 companies in the Drug Manufacturers industry, placing it in the top 0.90000000000001%.
Is Cipher Pharmaceuticals' FCF Margin % too high?
Cipher Pharmaceuticals' current FCF Margin % of 31.68% is 42% below median its 10-year median of 54.97. Over the past 10 years, this metric has ranged from a low of 20.47 to a high of 75.50. The Drug Manufacturers industry median FCF Margin % is 2.51. Cipher Pharmaceuticals' value of 31.68% is 1162.2% above this industry median. Based on the distribution chart, Cipher Pharmaceuticals ranks #9 out of 958 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Cipher Pharmaceuticals has a GF Score™ of 100/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cipher Pharmaceuticals' FCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Cipher Pharmaceuticals ranks #9 out of 958 companies for FCF Margin %. This places Cipher Pharmaceuticals in the top 1% of its industry — outperforming the majority of peers. The industry median FCF Margin % is 2.51. Cipher Pharmaceuticals' value of 31.68% is 1162.2% above this benchmark. Historically, Cipher Pharmaceuticals' own FCF Margin % has ranged from 20.47 to 75.50 over the past decade. While the company's 10-year median is 54.97 vs. the industry median of 2.51, Cipher Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.51, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cipher Pharmaceuticals's current FCF Margin % of 31.68% is 1162.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Cipher Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cipher Pharmaceuticals's current FCF Margin % is 31.68%, which is 42% below median its own 10-year median of 54.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cipher Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Cipher Pharmaceuticals (TSX:CPH) is currently considered Fairly Valued. The stock's GF Value™ is C$17.03, compared to a current price of C$16.47 — trading 3.3% below its estimated fair value. The current FCF Margin % is 31.68%, which is 42% below median its 10-year median of 54.97 and 1162.2% above the Drug Manufacturers industry median of 2.51. Cipher Pharmaceuticals' overall GF Score™ is 100/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Cipher Pharmaceuticals (TSX:CPH), the current FCF Margin % is 31.68% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cipher Pharmaceuticals (TSX:CPH) Overvalued in 2026?
Based on GuruFocus' analysis, Cipher Pharmaceuticals stock appears to be undervalued.
The current stock price of C$16.47 is trading 3.3% below its estimated GF Value™ of C$17.03.
GuruFocus considers Cipher Pharmaceuticals to be Fairly Valued.
Key valuation signals for TSX:CPH:
FCF Margin %: 31.68% (42% below median its 10-year median of 54.97)
GF Value™: C$17.03 vs. price of C$16.47 (3.3% below fair value)
Industry Position: 1162.2% above the Drug Manufacturers median (#9 of 958)
No single metric tells the full story. See the TSX:CPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cipher Pharmaceuticals Inc is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company is building its business through product acquisitions, out-licensing, and in-licensing arrangements. Its products include Dermatology Products, Hospital Acute Care Products, specialty medicines, and Out-Licensed Products, among others. The company's geographical operational areas include Canada and the United States.
100GF Score
Get the complete analysis for TSX:CPH
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:CPH has been successfully added to your 
